AMIVAS Launches Europe's First and Only Licensed Severe Malaria Treatment
AMIVAS Ireland Ltd (AMIVAS), a biopharmaceutical company focused on developing, commercialising, manufacturing and distributing artesunate for the treatment of severe malaria, today announced the launch of Artesunate AMIVAS in Europe and the U.K.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241017001569/en/
(Photo: Business Wire)
Artesunate AMIVAS is the first and only product licensed, manufactured in a regulated setting, and approved to treat severe malaria in the EU, European Area (EEA), and the U.K. Severe malaria is a disease that impacts an estimated 1,250 European travelers each year. Artesunate AMIVAS is sold as a 110-milligram powder and solvent combined to create an injectable solution.
Artesunate AMIVAS is now available from the Scandinavian distributor, Nordic Prime in Denmark, Finland, Sweden and Norway. To order, see https://www.nordicprime.dk/h
'The launch of Artesunate AMIVAS across Europe means that, for the first time, travelers to and from malaria-endemic regions of the world, and military personnel deployed there, now have access to a licensed, approved severe malaria treatment that could save their lives if needed, said Laura Walsh, AMIVAS Operations Director. 'Because of the well-established safety and efficacy profile of Artesunate AMIVAS, healthcare practitioners can now be confident when treating an adult or child diagnosed with severe malaria.'
'It is gratifying to be launching Artesunate AMIVAS in Europe after its successful launch in the United States,' said Sean Power, AMIVAS Director, Ireland. 'The AMIVAS mission is focused on bringing safe, effective, fully licensed and approved treatments to patients in need in order to extend and improve their lives. This launch milestone is clear proof of our commitment to that pledge.'
The U.S. Food and Drug Administration approved Artesunate for Injection™ in May, 2020 to treat severe malaria in adults and in children. AMIVAS (US) holds the license.
The European Union Commission awarded approval to AMIVAS Ireland to commercialise Artesunate Amivas in the EU and EEA in late 2021. Approval was granted by the U.K. MHRA in April, 2022.
About Severe Malaria
Malaria is a febrile disease caused by Plasmodium parasites and is usually transmitted by mosquitos. In 2020, almost half of the global population was at risk of contracting it. Over 400,000 deaths are recorded each year from the disease, with sub-Saharan Africa's population being most at risk. In Europe, 50 years after eradication, malaria is still a major health concern. While most infections in Europe are related to international travel, climatic changes are foreseen to enhance the risk for locally transmitted malaria infections in Europe. In Europe, peaks in the number of malaria cases occur July to September. Since the vast majority of malaria cases are imported, this could partly be linked to travellers returning from summer holidays. Malaria can progress to severe malaria, at which point the mortality rate approaches 100 percent if left untreated. Infants and children under five, pregnant women, and people with low immunity are at highest risk of developing severe malaria. Artesunate has been shown to improve survival rates, with particular benefit for patients with high parasitaemia. Complications of severe malaria include severe anaemia and signs of end-organ damage, such as coma (cerebral malaria), lung complications, hypoglycaemia (low glucose blood levels), or acute kidney injury.
Travelers can protect themselves before, during and after travel (https://www.ecdc.europa.eu/en/malaria).
About Artesunate AMIVAS
Intravenous artesunate has been the global standard of care for severe malaria for more than 20 years. Artesunate AMIVAS is approved for the initial treatment of severe malaria in adults and children by the U.S. Food and Drug Administration, the European Medicines Association, and the Medicine and Healthcare Product Regulatory Agency.
Artesunate is associated with up to a 34.7 percent reduction in risk of mortality compared with quinine. Supplied as a sterile powder, Artesunate can be safely stored at room temperature. Artesunate is easily prepared for use in one step.
Artesunate AMIVAS is superior to standard intravenous quinine in the most important clinical parameter, mortality. Artemisinins, the active ingredient in Artesunate AMIVAS, are the fastest-acting clinical anti-malarial compounds. They can be administered intravenously only when formulated to do so.
About AMIVAS
AMIVAS, based in Nassau, Delaware, in the United States, is a post-approval biopharmaceutical company, founded with a mission to improve and extend human lives by discovering, developing, and distributing new best-in-class medicines. AMIVAS responded to the urgent need for a United States- and European-based firm to assume responsibility for regulated manufacture and distribution of Artesunate after quinidine gluconate was discontinued in the U.S. in 2019. The Company achieved U.S. Food and Drug Administration approval for Artesunate for Injection – its first commercial product – in May, 2020. Artesunate for Injection is indicated for the treatment of severe malaria in adults and children. AMIVAS is committed to being the global leader in the battle against infectious diseases, driving scientific discovery and breakthroughs that will redefine the possibilities of critical medicines.
For more information, visit AMIVAS.com and follow AMIVAS on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017001569/en/
Media: Sheila Burke
Methodhealthcomms@gmail.com
+1-484-667-6330
© Business Wire, Inc. Disclaimer:
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Local France
6 hours ago
- Local France
Who works harder - the French or the Germans?
France's prime minister recently scolded his compatriots for not working enough, while the country's public accounts minister went further and said : "In France, we work 100 hours less per person than in Germany". The comments come in the context of France's fraught budget debates - the 2026 Budget aims to save €40 billion to finally get a handle on the country's spiralling budget deficit and one of the measures proposed is to axe two public holidays . But is it actually true, as minister Amélie de Montchalin says, that the Germans work harder than the French? Judging by the country's respective stereotypes, you would think it is - while Germans are clichéd as hard-working, efficient and (dare we say it?) just a touch humourless, the French are widely seen as far more interested in having a good lunch, a long holiday and perhaps a romantic encounter than they are in work. But stereotypes are not statistics, and here, the data tells an unexpected story. Advertisement De Montchalin's figures appear to be based on OECD data from 2024 which shows that France worked an average of 666 hours per capita, compared with 724 hours in Germany. Both countries are slackers by European standards - the European Union average is 776 hours. So case closed? Not quite. This data uses the crude metric of dividing the total numbers of hours worked per year by the country's population - and that's the whole ppopulation including children, pensioners, the unemployed and other people not in the workforce. This puts France at a disadvantage, because it it has a relatively high percentage of the population not in work, due to a combination of factors such as a long life expectancy which, coupled with an early retirement age, means that around a quarter of the population is retired . France also has a higher unemployment rate than Germany, but it also has a higher birth-rate meaning that there are more children who are not (yet) in the workforce. The OECD also publishes more nuanced data which looks at work hours divided by the total workforce - a more accurate measure of how hard each worker is actually working . On this metric, France wins - French workers work 1,494 hours per year, while Germans work 1,340 hours a year. Once again, both are below the EU average of 1,570 hours a year. The European champions/suckers are Greece, where people work 1,882 hours per year. Eurostat data backs up this picture, showing that on average French workers work 35.8 hours per week, while Germans work 33.9 hours per week (this data includes full time and part time workers). Advertisement Last year, France's Conseil d'analyse économique (council for economic analysis) published a study on the total number of working hours over time, comparing France, Germany, the UK and the USA. It shows a uniform decline in the number of hours worked in Europe from the 1970s, a trend that was reversed 20 years later - since the mid-1990s, the number of hours worked has been rising in France, Germany and the UK. So overall we can say that Germans are more likely to be part of the workforce than the French - but among those who do work, the French work more. It is still true that the French lunch break is widely observed, though, in fact the country's workplace code specifies that it is illegal to eat lunch while at your desk/work station .
Euronews
6 hours ago
- Euronews
Iceland to launch talks on security, defence partnership with EU
European Commission President Ursula von der Leyen said on Thursday that the EU will launch talks on a security and defence partnership with Iceland. "We will cooperate more closely on hybrid threat response, civil protection and secure communications," von der Leyen said in a post on X after a press conference in Keflavík with Iceland's Prime Minister Kristrún Frostadóttir. Frostadóttir said she was hopeful that talks would conclude by the end of the year. "This is very important for us to show that we can have cooperation on critical infrastructure, civil protection, any sort of dual use defence investment and this also includes hybrid and cyber threats," she said. This agreement with the EU is independent of Iceland's NATO membership and existing defence agreements with the United States, national public broadcaster RÚV said. "With this agreement, Iceland has also entered the European security and defines cooperation," von der Leyen said. "There are already eight allied countries, including Norway, the United Kingdom and Canada. With this agreement, you will gain access to our SAFE project, which invests around €150 billion per year in security and defence." At the meeting, Frostadóttir also said a comprehensive review of Iceland's terms of trade with the European Union, announced in December 2023, would start soon. Iceland's government said in December that it aims to put the question of EU membership to a referendum by 2027. Frostadóttir's administration also said it would set up a panel of experts to look into the advantages and disadvantages of retaining the Icelandic crown over adopting the Euro. According to a poll conducted last June by market research company Maskína, support for EU membership among Iceland's population is growing. That poll found just over 54% of respondents were in favour of joining the bloc, with the majority saying they thought households would be financially better off as part of the EU. That was a significant swing in favour of membership in a country that has generally been ambivalent about joining the EU.
Fashion Network
8 hours ago
- Fashion Network
Puig's quarterly sales rise a steady 8%
Spanish company Puig, known for its perfume brands Rabanne, Carolina Herrera and , said on Wednesday its second-quarter sales at constant currency rose 8% from a year ago, in line with the slowdown in growth the company expects for the year. See catwalk Puig reported 1.09 billion euros ($1.27 billion) in sales during the second quarter, in keeping with the 1.1 billion euros forecast by analysts in an LSEG poll, and achieving the same magnitude of revenue increase year-on-year as in the previous quarter. The Barcelona-based group confirmed that it expects revenue growth to decelerate to between 6% and 8% in 2025 after an 11% increase in 2024, as it navigates the challenge of expected higher tariffs in the United States, one of its biggest markets. Chairman and CEO Marc Puig said during a call with analysts that whatever tariffs will be, the impact this year "will be relatively minor because most of the stock is already in the United States". Sales in the Americas rose 10% in the quarter, despite trade tensions stemming from an initial 10% increase in U.S. tariffs and Washington's promise of more levies, while sales in Asia improved by 19.5%. Still, the EMEA region remains its main market. Puig has priced the additional 10% U.S. tariff into its annual sales projection. U.S. President Donald Trump on Saturday threatened to impose a 30% tariff on imports from the European Union starting on August 1, escalating trade tensions that may affect major beauty industry players such as L'Oreal, opens new tab and Estee Lauder, opens new tab, alongside other sectors such as European wine or clothing.
